HSIC Stock Might Rise Following the Acquisition of Acentus

Core Viewpoint - Henry Schein, Inc. has completed the acquisition of Acentus, enhancing its Home Solutions business and positioning itself better in the home medical supply market [1][5][6]. Company Summary - The acquisition of Acentus is expected to be neutral to 2025 non-GAAP earnings per share and accretive thereafter, although financial terms have not been disclosed [1]. - Following the acquisition announcement, HSIC shares decreased by 0.2% to $71.15, indicating a slight market reaction [2]. - With the addition of Acentus, Henry Schein's homecare medical products platform will have an annual revenue base of approximately$350 million [3]. - The company currently has a market capitalization of $8.98 billion, with 2025 earnings per share estimates remaining unchanged at$5.20 [4]. - Acentus, which has an annual revenue of approximately $35 million, will see its founders join Henry Schein as part of the acquisition [7]. Industry Summary - The global home healthcare market was valued at$390.24 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.96% from 2024 to 2030, driven by demand for cost-effective healthcare solutions and the rise of virtual care [8].